Chronic kidney disease is often described as a disorder of filtration, but its consequences extend far beyond the kidneys. One of its most dangerous complications is vascular calcification, a process in which the walls of arteries gradually accumulate mineral deposits and become stiff. A new study by Yang, Cheng, Jin and colleagues, published in Cell Death Discovery, identifies a molecular mechanism that may help explain how this transformation accelerates. The researchers report that HMGA1, a DNA-binding regulatory protein, drives vascular smooth muscle cells toward an osteogenic, or bone-forming, identity by increasing transcription of the inflammatory cytokine interleukin-1 beta, known as IL-1β.
Vascular smooth muscle cells normally occupy the muscular middle layer of arteries, where they contract and relax to control vessel diameter and blood pressure. In chronic kidney disease, however, the biochemical environment surrounding these cells is profoundly altered. Disturbances in phosphate and calcium balance, oxidative stress, uremic toxins and persistent inflammation can push the cells away from their contractile state. Instead of maintaining the vessel wall, they begin expressing genes associated with osteoblasts, the cells responsible for producing bone matrix. This phenomenon is known as osteogenic phenotype transdifferentiation and is a central biological event in arterial calcification.
The new work places HMGA1 at the center of this cellular reprogramming process. HMGA1, or high mobility group AT-hook 1, is a chromatin-associated protein that does not function like a conventional enzyme. Rather than catalyzing a chemical reaction, it binds to particular regions of DNA and changes the three-dimensional organization of chromatin, the complex of DNA and proteins that packages genetic material. By altering how DNA is folded and made accessible, HMGA1 can help activate broad transcriptional programs involved in development, proliferation and inflammation. Its influence is therefore potentially powerful: a change in HMGA1 activity can reshape the expression of many genes at once.
According to the study, HMGA1 accelerates the osteogenic conversion of vascular smooth muscle cells by elevating transcription of the gene encoding IL-1β. Transcription is the first major step in gene expression, during which the information stored in DNA is copied into messenger RNA. Increased IL-1β transcription can lead to greater production of this potent inflammatory signal, which is then released or processed to influence neighboring cells and local tissue behavior. In the arterial wall, that inflammatory amplification may help establish conditions that favor mineral deposition and the loss of the cells’ normal contractile identity.
IL-1β is a member of the interleukin-1 cytokine family and is widely recognized as a major regulator of innate immunity. It can activate inflammatory gene networks, alter cellular metabolism and affect the behavior of multiple cell types. Its activity is tightly controlled under healthy conditions because excessive or prolonged signaling can damage tissues. In chronic kidney disease, where inflammation may persist for years, increased IL-1β production could provide a molecular bridge between systemic disease and local vascular injury. The study’s central implication is that HMGA1 may intensify this bridge by turning on IL-1β at the level of gene transcription.
The connection is important because vascular calcification is not simply passive precipitation of calcium and phosphate. It is an active, cell-regulated process that resembles aspects of skeletal development. Transformed vascular smooth muscle cells can lose contractile proteins while gaining osteogenic regulators and proteins associated with mineralized matrix formation. Once this program is established, the arterial wall may become progressively less flexible. Stiffened arteries increase the workload on the heart, interfere with normal blood-flow regulation and are associated with elevated risks of cardiovascular events in people with impaired kidney function.
By identifying HMGA1 as an upstream regulator of IL-1β transcription, the research may point toward a more precise way of understanding this disease pathway. Targeting inflammation alone may not fully address the problem if the chromatin changes that sustain inflammatory gene expression remain active. Conversely, interfering with HMGA1 could theoretically influence several downstream processes at once, including the inflammatory signals that help drive osteogenic transdifferentiation. Such an approach would require careful development, however, because HMGA1 participates in normal gene regulation and has been linked to essential processes such as cell growth and tissue development.
The findings also highlight the growing importance of epigenetic and transcriptional control in chronic kidney disease complications. Traditional models of vascular calcification have focused heavily on circulating minerals, but the behavior of the vascular cells themselves is equally important. A protein such as HMGA1 can function as a molecular interpreter, translating inflammatory and metabolic stress into altered chromatin accessibility and changes in cell identity. Understanding that process could help explain why some patients develop severe arterial calcification even when conventional risk factors appear similar.
The study does not, by itself, establish a ready-to-use treatment, and questions remain about how HMGA1 and IL-1β interact across different stages of chronic kidney disease. Future work will need to determine whether blocking this pathway can prevent or reverse vascular calcification in living organisms, whether it can be targeted safely in human patients and how it interacts with phosphate control, dialysis and existing anti-inflammatory strategies. Nevertheless, the research provides a compelling molecular narrative: in diseased arteries, HMGA1 may open the genetic circuitry that elevates IL-1β, helping vascular smooth muscle cells abandon their normal identity and adopt a bone-like program.
Subject of Research: HMGA1-driven osteogenic phenotype transdifferentiation of vascular smooth muscle cells and its role in chronic kidney disease-associated vascular calcification.
Article Title: HMGA1 accelerates vascular smooth muscle cell osteogenic phenotype transdifferentiation by elevating pro-inflammatory cytokine IL-1β transcription in chronic kidney disease.
Article References: Yang, B., Cheng, M., Jin, J. et al. “HMGA1 accelerates vascular smooth muscle cell osteogenic phenotype transdifferentiation by elevating pro-inflammatory cytokine IL-1β transcription in chronic kidney disease.” Cell Death Discovery (2026). https://doi.org/10.1038/s41420-026-03271-z
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41420-026-03271-z
Keywords: chronic kidney disease, vascular calcification, vascular smooth muscle cells, HMGA1, IL-1β, inflammation, osteogenic transdifferentiation, chromatin regulation, cardiovascular disease
Tags: chronic kidney disease complicationsDNA-binding regulatory proteins in vascular healthHMGA1 role in vascular smooth muscle cell transformationIL-1β in vascular osteogenic differentiationinflammation and vascular calcificationmolecular mechanisms of arterial calcificationosteogenic transdifferentiation in blood vesselsoxidative stress and vascular cell transformationphosphate and calcium imbalance in CKDregulation of vascular cell phenotypevascular calcification in chronic kidney diseasevascular smooth muscle cell plasticity
